The authors have declared that no competing interests exist.
Conceived and designed the experiments: HK SW UA CM KRP THB BA MW. Performed the experiments: SW UA CM SFR. Analyzed the data: HK QdM SW PS UA CM SFR KRP THB BA AvdV MW. Wrote the paper: HK QdM SW KRP THB BA AvdV MW.
Current address: Naval Medical Research Center, Silver Spring, Maryland, United States of America.
Current address: Walter Reed National Military Medical Center, Bethesda, Maryland, United States of America.
Chikungunya virus (CHIKV) is known to cause sporadic or explosive outbreaks. However, little is known about the endemic transmission of CHIKV. To ascertain the endemic occurrence of CHIKV transmission, we tested blood samples from patients with a non-dengue febrile illness who participated in a prospective cohort study of factory workers in Bandung, Indonesia. From August 2000 to June 2004, and September 2006 to April 2008, 1901 febrile episodes occurred and 231 (12.2%) dengue cases were identified. The remaining febrile cases were evaluated for possible CHIKV infection by measuring anti-CHIKV IgM and IgG antibodies in acute and convalescent samples. Acute samples of serologically positive cases were subsequently tested for the presence of CHIKV RNA by RT-PCR and/or virus isolation. A total of 135 (7.1%) CHIKV infections were identified, providing an incidence rate of 10.1/1,000 person years. CHIKV infections were identified all year round and tended to increase during the rainy season (January to March). Severe illness was not found and severe arthralgia was not a prominently reported symptom. Serial post-illness samples from nine cases were tested to obtain a kinetic picture of IgM and IgG anti-CHIKV antibodies. Anti-CHIKV IgM antibodies were persistently detected in high titers for approximately one year. Three patients demonstrated evidence of possible sequential CHIKV infections. The high incidence rate and continuous chikungunya cases in this adult cohort suggests that CHIKV is endemically transmitted in Bandung. Further characterization of the circulating strains and surveillance in larger areas are needed to better understand CHIKV epidemiology in Indonesia.
Chikungunya is one of the neglected diseases. It has only attracted attention during outbreaks, in particular, the large epidemics in the Indian Ocean in 2005–2006. To our knowledge, there has never been any surveillance to determine the transmission of this virus among humans in non-outbreak settings. Such surveillance is particularly important because it will provide a better estimate of the disease burden and valuable information on how this virus is maintained outside outbreaks. Our study, conducted between 2000 and 2008 in Bandung, West Java, Indonesia, yielded several important findings: 1. Chikungunya is an important cause of fever among adults in Bandung, Indonesia. 2. The clinical symptoms are mostly mild and short lasting. 3. In addition to previously described epidemiological features involving episodic outbreaks, it is also continuously transmitted throughout the year. 4. A few patients may have experienced more than one chikungunya virus infection. 5. Only the Asian genotype was found and not the East Central South African genotype that was responsible for the 2005 outbreak in the Indian Ocean. 6. The persistence of IgM for a long period after illness may complicate the interpretation of laboratory results.
Chikungunya virus (CHIKV) is an arthropod-borne virus belonging to the genus
CHIKV in Africa is predominantly maintained in an inter-epidemic sylvatic cycle in which the virus resides in wild primates and mosquitoes such as
In Indonesia, chikungunya was first reported in 1982 in East Sumatera. It then spread to other islands including Java, Kalimantan, Bali, Flores and Sulawesi
This study was a part of “An epidemiology study of dengue and dengue hemorrhagic fever in adults”, approved by the Institutional Review Board of NAMRU#2, Jakarta (IRB#30855 and N2.2006.0001) and the National Institute of Health Research and Development (NIHRD), Ministry of Health, Indonesia (KS 02.02.2.1.2181, KS 02.01.2.1732 and KS.02.01.2.1.2776) in compliance with all U.S. Federal Regulations governing the protection of human subjects. Details of the study design are described elsewhere
Convalescent sera from febrile volunteers who had been excluded as dengue cases were first tested to detect CHIKV IgM antibodies using enzyme-linked immunosorbent assay (ELISA). When positive, paired acute and convalescent sera were further tested for CHIKV IgM and IgG antibodies using an ELISA, and acute sera were processed for viral isolation and/or tested by RT-PCR to detect CHIKV genomes. CHIKV infection was confirmed when CHIKV genome or virus was detected, or when either seroconversion or a four-fold rise in titers of anti-CHIKV IgM and IgG antibodies was detected.
Serum samples were assayed for the presence of IgG and IgM antibodies against CHIKV using ELISA as previously described
The kinetics of IgM and IgG antibodies to CHIKV were analyzed using specimens from the first nine patients who had complete serial quarterly serosurvey sera for two years.
Acute sera from cases diagnosed by seroconversion or a four-fold increase of anti-CHIKV IgM and IgG antibody titers were processed for virus isolation and analysis by RT-PCR. The methods used to perform these assays have been described previously
Sequencing of the structural polyprotein coding region of 20 chikungunya virus isolates was performed (Genbank accession numbers: KC879559–KC879578), using primers that were previously described
Sequence data analysis was performed using Sequencher 3.1 (Genecodes, Ann Arbor, MI) with the default parameters to improve the overall sequence quality. ClustalX 2.0.9
Descriptive data (mean age and standard deviation) were analyzed using STATA version 9.0 (StataCorp 2005, College Station, TX).
A total of 4380 volunteers were enrolled into the study, consisting of 1324 volunteers who joined from the beginning of this study (August 2000), 1654 who discontinued their participations after the first phase (June 2004) and 1402 new enrollees in the second phase (September 2006 to April 2008). The mean (SD) age and age range of volunteers at enrollment were 37.1 (±7.7) and 18 to 66 years old. A higher proportion of the study population was male (ratio 1.85∶ 1).
A total of 1431 acute febrile episodes (AFE) occurred among 2978 volunteers in the first phase of the study, which lasted for 47 months. CHIKV infection was identified in 96 (6.7%) of these AFE, yielding a yearly incidence rate of 10.1 per 1,000 persons. During the second phase of the study in which 2726 volunteers were followed for 20 months, 39 chikungunya cases were diagnosed among 470 AFE, resulting in a slightly higher percentage and incidence rate (8.3% and 10.3/1,000 persons/year). In total, the percentage and incidence rate were 7.1% and 10.1/1,000 (persons/year), respectively. The number of chikungunya cases per month over the years and the total number of cases per year are shown in
The number of CHIK cases per month is represented by skinny black rectangles. The total number of cases for a year is indicated by light gray rectangles and the incidence rate for a year is indicated by dark gray rectangles. The rectangles representing annual data are placed at the midpoint (July) for their respective year.
In 69 (51.1%) of the 135 CHIKV infections, the diagnosis of acute CHIKV infection was confirmed by positive RT-PCR, viral isolation and serology results. In 47 (34.8%) cases the diagnosis was confirmed by positive RT-PCR and serology results, while 19 (14.1%) cases only had serological evidence of CHIK infection. Of these 19 cases, 10 were negative for RT-PCR and isolation, eight did not have RT-PCR performed and one did not have viral isolation performed due to an insufficient volume of serum.
Post-illness sera from nine patients, who had serial specimens taken during serosurveys over two years, were tested to evaluate the kinetics of CHIKV IgM and IgG antibodies (
The mean +/− SD titer for each timepoint (W = weeks, M = months) after illness onset. N = the number of samples for a given timepoint.
CHIKV could be isolated from specimens collected until day 4 of the illness whereas RNA was detectable by RT-PCR until 6 days post illness onset. Sequencing analysis was performed on 20 isolates from the first and second phases of the study. All isolates had alanine at position 226 in the E1 gene. Nucleotide similarity between these isolates was >99.4%, and amino acid similarity was >99.7%. A phylogenetic tree was constructed based on 1320 bases of the structural polyprotein coding region. All samples sequenced from this study clustered together and belong to the Asian genotype (
Neighbor-joining tree of the structural polyprotein coding region of CHIKV. The sequences obtained in this study are highlighted in bold. Numbers indicate bootstrap values for the groups to the right.
Most patients came to the clinic on day two or three of fever (57 and 56 patients out of 135 patients, respectively).
| Symptoms | N | % Pos |
| Myalgia | 124/134 | 92.5 |
| Headache | 119/134 | 88.8 |
| Arthralgia | ||
| 1st phase | 37/95 | 38.9 |
| 2nd phase | 34/39 | 87.2 |
| Nausea | 71/134 | 53.0 |
| Retro-orbital pain | 51/134 | 38.1 |
| Cough | 37/134 | 27.6 |
| Abdominal Pain | 33/134 | 24.6 |
| Sore throat | 31/134 | 23.1 |
| Coryza | 31/134 | 23.1 |
| Rash | 17/134 | 12.7 |
| Vomiting | 15/134 | 11.2 |
| Diarrhea | 14/134 | 10.4 |
| Leukopenia(<4000/mm3) | 20/134 | 14.9 |
| Thrombocytopenia (<150,000/mm3) | 15/134 | 11.2 |
We identified two patients with a laboratory confirmed acute CHIKV infection in whom serology results on a blood sample collected three months before illness suggested a previous CHIKV infection. In the first volunteer, an acute CHIKV infection was confirmed by RT-PCR, virus isolation and serology. In the second patient, CHIKV infection was confirmed by RT-PCR and serology (
| ID Number | First infection | Second infection | ||
| Date of illness | Lab results | Date of illness | Lab results | |
| 005-1411 | unknown | Pre-illness specimen | 4 JAN2003 | Positive RT-PCR and |
| (21 SEP 2002) | Isolation | |||
| CHIKV IgM: 400 | CHIKV IgM: 800 to 400 | |||
| CHIK IgG: 800 | CHIKV IgG: 6400 to 6400 | |||
| 005-2048 | unknown | Pre-illness specimen | 6 MAR2001 | Positive RT-PCR |
| (25 NOV2000) | CHIKV IgM: 100 to 400 | |||
| CHIKV IgM: 400 | CHIKV IgG: 3200 to 6400 | |||
| CHIK IgG: 800 | ||||
| 005-1449 | 11 JUN 2002 | Positive RT-PCR and | 19 DEC2006 | Negative RT-PCR and |
| Isolation | Isolation | |||
| CHIKV IgM: neg to 6400 | CHIKV IgM: 400–1600 | |||
| CHIKV IgG: neg to 100 | CHIKV IgG: 1600–6400 | |||
Our studies, conducted between 2000 and 2008 in a large town in West Java, Indonesia, revealed several important epidemiological findings, including: 1. Among adults, CHIKV was an important cause of acute febrile illness. 2. CHIKV infections did not occur in epidemics as commonly reported, but were found throughout the year. 3. The clinical symptoms of CHIKV infection in this cohort were mostly mild and short-lived. 4. CHIKV infections were caused by the Asian genotype and not by the mutated East Central South African strain (ECSA), although only a limited number of samples were genotyped. 5. The persistence of IgM for a long period after illness may complicate the interpretation of laboratory results, and finally 6. We found evidence of possible recurrent CHIKV infections. We have previously reported an incidence rate of acute dengue of 18.1 cases per 1,000 persons per year (15.9% of febrile episodes) in the same cohort in 2000 to 2002
Another finding of our study was that chikungunya infections were generally mild and of short duration. Only two-thirds of cases requested medical leave from work, with most only requesting 2–3 days of leave. The percentage of chikungunya cases in our study that were hospitalized was significantly lower than for the dengue cases detected in our study (unpublished data). Additionally, during the first phase of our study, when data on arthralgia was not specifically asked, only 38.9% of volunteers reported it as a chief or other complaint, suggesting this symptom was minor or absent. Also, we did not find volunteers with prolonged illness or complications. Similar to our clinical findings, mild chikungunya cases were also reported among young migrant workers in Singapore during a 2008 outbreak
Genotyping of the CHIKV in twenty patients showed that infections were caused by the Asian genotype and not the ECSA genotype, which was responsible for the 2005 outbreak in the Indian Ocean and has since then spread to India and Southeast Asia, causing unprecedented nationwide outbreaks in Malaysia, Singapore and Thailand
According to our literature review, CHIKV infections have commonly been associated with outbreaks
One of the powerful features of our prospective cohort study was that volunteers were followed for several years. Therefore, we were able to observe the kinetics of CHIKV IgM and IgG antibodies longitudinally after infection. Our finding that IgM antibodies could be detected beyond one year was consistent with previous reports
Persistence of IgM antibodies also has consequences for diagnostics. In the absence of virus culture or RT-PCR, IgM and IgG serology assays should be conducted using paired sera collected at least 10 days apart to confirm the increasing titers. We also identified three patients (2%) with symptomatic CHIKV infections with laboratory features suggestive of possible secondary chikungunya infection, which, to our knowledge, has not yet been reported. Indeed, the current dogma holds that CHIKV infection will provide life-long immunity
Our study has some limitations. First, data on arthralgia as a symptom during the first phase of the study was collected based on passive reports from patients during their visits. On the other hand, it may also provide us some information regarding the percentage of patients who consider arthralgia as a prominent symptom. Listing arthralgia as one of the subjective symptoms that should be routinely included in questionnaires during acute illness may unintentionally increase the likelihood of subjects endorsing this symptom. Second, as mentioned above, the diagnosis of previous infections in two cases and recurrent infection in one case was based solely on results obtained by ELISA. Detecting the presence of virus either by tissue culture isolation or RT-PCR, or performing plaque reduction neutralization assays on the serum samples would have provided more definitive evidence for recurrent infections
In conclusion, our findings provide an estimate of the disease burden of CHIKV infections in Bandung, Indonesia and especially provide new information on its endemic transmission during inter-epidemic periods. These data highlight the importance of considering chikungunya in the differential diagnoses of acute febrile illnesses. Further studies are required to determine the significance of persistent IgM antibodies and the relation to arthralgia, the possibility of repeat CHIKV infections and the differences between strains in their potential to cause severe illness and epidemic versus endemic transmission. In addition, national surveillance needs to be established to monitor for the possible introduction of the ECSA genotype into Indonesia, as the transmission of this genotype may have a greater impact on public health. Finally, our findings highlight the need for development of affordable and sensitive rapid antigen diagnostic tests for early diagnosis of CHIKV infections and the need for a vaccine, especially since vector control has been unsuccessful so far.
(DOCX)
Click here for additional data file.
We would like to thank all volunteers for their valuable working hours, Dr. Ardini Raksanegara and Ms. Hodijah at the factory clinics, research teams from the Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital and NAMRU#2 for their dedication to this study, Wibowo Arindrarto for his work on chikungunya sequencing of 2001–2004 isolates, Kendra Chittenden from USAID Indonesia and Indonesia Research Partnership on Infectious Diseases (INA-RESPOND) for their support during the preparation of this manuscript.